Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Polacino PS, Stallard V, Klaniecki JE, Pennathur S, Montefiori DC, Langlois AJ, Richardson BA, Morton WR, Benveniste RE, Hu SL.

J Virol. 1999 Oct;73(10):8201-15.

2.

Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.

Polacino P, Stallard V, Klaniecki JE, Montefiori DC, Langlois AJ, Richardson BA, Overbaugh J, Morton WR, Benveniste RE, Hu SL.

J Virol. 1999 Jan;73(1):618-30.

3.

Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.

Langlois AJ, Desrosiers RC, Lewis MG, KewalRamani VN, Littman DR, Zhou JY, Manson K, Wyand MS, Bolognesi DP, Montefiori DC.

J Virol. 1998 Aug;72(8):6950-5.

4.

Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection.

Hu SL, Polacino P, Stallard V, Klaniecki J, Pennathur S, Travis BM, Misher L, Kornas H, Langlois AJ, Morton WR, Benveniste RE.

Immunol Lett. 1996 Jun;51(1-2):115-9.

PMID:
8811354
5.

Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

Javaherian K, Langlois AJ, Montefiori DC, Kent KA, Ryan KA, Wyman PD, Stott J, Bolognesi DP, Murphey-Corb M, Larosa GJ.

J Virol. 1994 Apr;68(4):2624-31.

6.

Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.

Haynes BF, Torres JV, Langlois AJ, Bolognesi DP, Gardner MB, Palker TJ, Scearce RM, Jones DM, Moody MA, McDanal C, et al.

J Immunol. 1993 Aug 1;151(3):1646-53.

PMID:
8335949
7.

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.

Haynes BF, Arthur LO, Frost P, Matthews TJ, Langlois AJ, Palker TJ, Hart MK, Scearce RM, Jones DM, McDanal C, et al.

J Exp Med. 1993 Mar 1;177(3):717-27.

8.

Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160.

Hu SL, Stallard V, Abrams K, Barber GN, Kuller L, Langlois AJ, Morton WR, Benveniste RE.

J Med Primatol. 1993 Feb-May;22(2-3):92-9.

PMID:
8411113
9.

SIV neutralization epitopes.

Javaherian K, Langlois AJ, LaRosa GJ.

Chem Immunol. 1993;56:78-90. Review. No abstract available.

PMID:
7680868
10.

Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus.

Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP.

AIDS Res Hum Retroviruses. 1992 Sep;8(9):1641-52.

PMID:
1457210
11.

Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection.

Hu SL, Travis BM, Stallard V, Abrams K, Misher L, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, et al.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1489-94. No abstract available.

PMID:
1466988
12.

A formalin-fixed whole SIV vaccine induces protective responses that are cross-protective and durable.

Murphey-Corb M, Ohkawa S, Davison-Fairburn B, Martin LN, Baskin GB, Langlois AJ, McIntee M, Narayan O, Gardner MB.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1475-8. No abstract available.

PMID:
1466986
13.

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.

Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, Mercer J, Eastman DJ, Lucas C, Langlois AJ, et al.

J Virol. 1992 Jul;66(7):4464-9.

14.

The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.

Javaherian K, Langlois AJ, Schmidt S, Kaufmann M, Cates N, Langedijk JP, Meloen RH, Desrosiers RC, Burns DP, Bolognesi DP, et al.

Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418-22.

15.

Evaluation of protective efficacy of recombinant subunit vaccines against simian immunodeficiency virus infection of macaques.

Hu SL, Abrams K, Misher L, Stallard V, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE.

J Med Primatol. 1992 Feb-May;21(2-3):119-25.

PMID:
1433262
16.

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE.

Science. 1992 Jan 24;255(5043):456-9.

PMID:
1531159
17.

The ability of certain SIV vaccines to provoke reactions against normal cells.

Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP.

Science. 1992 Jan 17;255(5042):292-3. No abstract available.

PMID:
1549775
18.

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications.

LaRosa GJ, Weinhold K, Profy AT, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Bolognesi DP, Matthews TJ, Emini EA, et al.

Science. 1991 Sep 6;253(5024):1146. No abstract available.

PMID:
1887238
19.

In vitro assays for detecting neutralizing and fusion-inhibiting antibodies to SIVMAC251.

Langlois AJ, Weinhold KJ, Matthews TJ, Bolognesi DP.

AIDS Res Hum Retroviruses. 1991 Aug;7(8):713-20.

PMID:
1718347
20.

Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages.

Shadduck PP, Weinberg JB, Haney AF, Bartlett JA, Langlois AJ, Bolognesi DP, Matthews TJ.

J Virol. 1991 Aug;65(8):4309-16.

21.

Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain.

Ivanoff LA, Looney DJ, McDanal C, Morris JF, Wong-Staal F, Langlois AJ, Petteway SR Jr, Matthews TJ.

AIDS Res Hum Retroviruses. 1991 Jul;7(7):595-603.

PMID:
1768461
22.

Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.

Cummins LM, Weinhold KJ, Matthews TJ, Langlois AJ, Perno CF, Condie RM, Allain JP.

Blood. 1991 Mar 1;77(5):1111-7.

PMID:
1995097
23.

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: corrections and clarifications.

LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, et al.

Science. 1991 Feb 15;251(4995):811. No abstract available.

PMID:
1990444
24.

HIV-1 neutralizing antibody and approaches to the envelope diversity problem.

Matthews TJ, Langlois AJ, Butto S, Bolognesi D, Javaherian K.

Adv Exp Med Biol. 1991;303:23-6. No abstract available.

PMID:
1725234
25.

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Javaherian K, Langlois AJ, LaRosa GJ, Profy AT, Bolognesi DP, Herlihy WC, Putney SD, Matthews TJ.

Science. 1990 Dec 14;250(4987):1590-3. Erratum in: Science 1991 Jan 4;251(4989):13.

PMID:
1703322
26.

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

Tyler DS, Stanley SD, Zolla-Pazner S, Gorny MK, Shadduck PP, Langlois AJ, Matthews TJ, Bolognesi DP, Palker TJ, Weinhold KJ.

J Immunol. 1990 Nov 15;145(10):3276-82.

PMID:
1700004
27.

Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.

Carlson JR, McGraw TP, Keddie E, Yee JL, Rosenthal A, Langlois AJ, Dickover R, Donovan R, Luciw PA, Jennings MB, et al.

AIDS Res Hum Retroviruses. 1990 Nov;6(11):1239-46.

PMID:
2078406
28.

Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

Hart MK, Palker TJ, Matthews TJ, Langlois AJ, Lerche NW, Martin ME, Scearce RM, McDanal C, Bolognesi DP, Haynes BF.

J Immunol. 1990 Oct 15;145(8):2677-85.

PMID:
1698859
29.

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, et al.

Science. 1990 Aug 24;249(4971):932-5. Erratum in: Science. 1991 Feb 15;251(4995):811.

PMID:
2392685
30.

Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Arthur LO, Bess JW Jr, Waters DJ, Pyle SW, Kelliher JC, Nara PL, Krohn K, Robey WG, Langlois AJ, Gallo RC, et al.

J Virol. 1989 Dec;63(12):5046-53.

31.

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, et al.

Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72.

32.

Barrier protection against the human immunodeficiency virus.

Tyler DS, Lyerly HK, Nastala CL, Shadduck PP, Fitzpatrick KT, Langlois AJ, Moylan JA.

Curr Surg. 1989 Jul-Aug;46(4):301-4. No abstract available.

PMID:
2766799
33.

Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals.

Kenealy WR, Matthews TJ, Ganfield MC, Langlois AJ, Waselefsky DM, Petteway SR Jr.

AIDS Res Hum Retroviruses. 1989 Apr;5(2):173-82.

PMID:
2469449
34.

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Skinner MA, Langlois AJ, McDanal CB, McDougal JS, Bolognesi DP, Matthews TJ.

J Virol. 1988 Nov;62(11):4195-200.

35.

B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Schrier RD, Gnann JW Jr, Langlois AJ, Shriver K, Nelson JA, Oldstone MB.

J Virol. 1988 Aug;62(8):2531-6.

36.

Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.

Skinner MA, Ting R, Langlois AJ, Weinhold KJ, Lyerly HK, Javaherian K, Matthews TJ.

AIDS Res Hum Retroviruses. 1988 Jun;4(3):187-97.

PMID:
2456088
37.

Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals.

Weinhold KJ, Lyerly HK, Matthews TJ, Tyler DS, Ahearne PM, Stine KC, Langlois AJ, Durack DT, Bolognesi DP.

Lancet. 1988 Apr 23;1(8591):902-5.

PMID:
2895830
38.

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, Haynes BF.

Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6.

39.

Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay.

Langlois AJ, Matthews TJ, Weinhold KJ, Chaffee S, Hershfield M, Bolognesi DP.

AIDS Res Hum Retroviruses. 1988 Feb;4(1):63-9. Erratum in: AIDS Res Hum Retroviruses 1988 Jun;4(3):237.

PMID:
3163254
40.

3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

St Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ, Furman PA.

Antimicrob Agents Chemother. 1987 Dec;31(12):1972-7.

41.

Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.

Rusche JR, Lynn DL, Robert-Guroff M, Langlois AJ, Lyerly HK, Carson H, Krohn K, Ranki A, Gallo RC, Bolognesi DP, et al.

Proc Natl Acad Sci U S A. 1987 Oct;84(19):6924-8.

42.

Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

Matthews TJ, Weinhold KJ, Lyerly HK, Langlois AJ, Wigzell H, Bolognesi DP.

Proc Natl Acad Sci U S A. 1987 Aug;84(15):5424-8.

43.
44.

A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.

Palker TJ, Matthews TJ, Clark ME, Cianciolo GJ, Randall RR, Langlois AJ, White GC, Safai B, Snyderman R, Bolognesi DP, et al.

Proc Natl Acad Sci U S A. 1987 Apr;84(8):2479-83.

45.

Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.

Lyerly HK, Reed DL, Matthews TJ, Langlois AJ, Ahearne PA, Petteway SR Jr, Weinhold KJ.

AIDS Res Hum Retroviruses. 1987;3(4):409-22.

PMID:
2833917
46.

Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.

Matthews TJ, Langlois AJ, Robey WG, Chang NT, Gallo RC, Fischinger PJ, Bolognesi DP.

Haematol Blood Transfus. 1987;31:414-22.

PMID:
2832276
47.

Prospects for development of a vaccine against HTLV-III-related disorders.

Matthews TJ, Lyerly HK, Weinhold KJ, Langlois AJ, Rusche J, Putney SD, Gallo RC, Bolognesi DP.

AIDS Res Hum Retroviruses. 1987;3 Suppl 1:197-206. Review. No abstract available.

PMID:
2825738
48.

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

Putney SD, Matthews TJ, Robey WG, Lynn DL, Robert-Guroff M, Mueller WT, Langlois AJ, Ghrayeb J, Petteway SR Jr, Weinhold KJ, et al.

Science. 1986 Dec 12;234(4782):1392-5.

PMID:
2431482
49.

Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Matthews TJ, Langlois AJ, Robey WG, Chang NT, Gallo RC, Fischinger PJ, Bolognesi DP.

Proc Natl Acad Sci U S A. 1986 Dec;83(24):9709-13.

50.

Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A.

Langlois AJ, Matthews TJ, Weinhold KJ, Bolognesi DP.

J Natl Cancer Inst. 1985 Oct;75(4):709-15.

PMID:
3862903

Supplemental Content

Loading ...
Support Center